Income Statement

v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 20,518 $ 10,124
Operating expenses:    
Cost of implants and other costs 1,535 632
Research and development 197,849 658,237
Selling, general and administrative 938,945 911,093
Depreciation and amortization 6,863 19,378
Total operating expenses 1,145,192 1,589,340
Loss from operations (1,124,674) (1,579,216)
Other income (expenses):    
Interest expense, net (166,776) (123,308)
Grant income 346,393 90,232
Other miscellaneous income 66 28,229
Total other income (expense) 179,683 (4,847)
Net loss before provision for income taxes (944,991) (1,584,063)
Income taxes 0 0
Net loss (944,991) (1,584,063)
Non-controlling interest 551 776
Net loss attributable to BioCorRx Inc. $ (944,440) $ (1,583,287)
Net loss per common share, basic and diluted $ (0.14) $ (0.26)
Weighted average number of common shares outstanding, basic and diluted 6,931,759 6,018,763

Source